Why would Martin Shkreli hike an old drug price by 5,000%? Only a 'moron' would ask; Why Axovant's $315M IPO bonanza should scare the hell out of you; and more.
Novo Nordisk signed a deal with Ablynx worth up to €377 million ($400 million) to collaborate on so-called nanobodies, antibody fragments designed to split the difference between biologics and small-molecule drugs.
Allergan, seeking to burnish its reputation in R&D, bought into some early-stage treatments for autism and obsessive-compulsive disorder as it prepares to join forces with Pfizer in a massive merger.
Heptares Therapeutics, acquired by Japan's Sosei earlier this year, signed a deal with Teva Pharmaceutical to co-develop novel migraine treatments, getting in line for as much as $410 million.
BioMarin's odds of winning FDA approval for a Duchenne muscular dystrophy treatment got longer on Tuesday after a group of agency advisers picked apart the company's clinical evidence and raised serious concerns about its safety.
Shire is reportedly preparing a new cash-plus-stock offer for Baxalta. The report comes almost four months after a $30 billion all-stock proposal was dismissed by Baxalta, leaving Shire to ponder how to advance its ambitions to become a rare disease powerhouse.
Eli Lilly won FDA approval for a lung cancer treatment that posted only a marginal survival benefit in late-stage clinical trials, gaining clearance to treat a small population of patients with particularly serious disease.
Presage Biosciences, a popular partner for oncology drug developers, is wading into clinical development of its own, in-licensing a candidate and using its technology to spotlight potential combination therapies.
Aduro BioTech, developing an immunotherapy combination treatment for cancer, watched its share price dip on Tuesday after quietly disclosing that a trial patient developed a serious infection tied to the company's re-engineered bacterial treatment.
The so-called 21st Century Cures Act, now making its way through Congress, is designed to speed up the FDA review process for potentially lifesaving medicines by encouraging approvals based on midstage data. But a new case study takes a look at what might have happened if a trio of once-promising Alzheimer's drugs had made it to market before their eventual Phase III failures, painting a grim picture of the bill's potential.
Wilex has pitched a funding plan to keep its R&D operation going for another 12 months. The aim is to round up enough money to advance an antibody-drug conjugate toward the clinic by supplementing €10 million ($10.6 million) from dievini Hopp BioTech with cash from other sources.
Belgian VC shop V-Bio Ventures has raised €63 million ($67 million) to invest in life science startups. The newly formed fund has a remit to back new and emerging biotechs from across Europe, but with strong ties to VIB, the Belgian research institute that spawned Ablynx, is likely to funnel a chunk of its cash into local companies.
AstraZeneca has unveiled a clutch of deals to add to the technological capabilities of its new R&D hub in Cambridge, U.K. The agreements will equip the site with robots to carry out high-throughput screening, sound wave tools to dispense compounds and software to share data with external partners.
ProQR Therapeutics has pushed back the date on which it expects to deliver data from its cystic fibrosis clinical trials. The delay means it may be late 2016 before ProQR presents data on its challenger to Vertex Pharmaceuticals' grip on the cystic fibrosis market.
Bristol-Myers Squibb has won yet another approval for its pioneering immuno-oncology drug Opdivo. The regulatory nod in advanced renal cell carcinoma, a form of kidney cancer, comes just one week after the FDA accepted the filing for priority review.
FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss the long-awaited merger agreement between Pfizer and Allergan, Martin Shkreli's CEO double duty, and the whimpering conclusion of two hostile takeovers.
Texas upstart XBiotech made a string of embarrassing mistakes in a Phase III trial on its lead cancer therapy, misdosing some patients and failing to adequately test others on the way to a staggering mishap.
Genmab's plans to develop ofatumumab for lymphoma came to a halt as the company pulled the plug early on a Phase III trial that was unlikely to meet its goals, souring an investment from partner Novartis.
Seres Therapeutics, one of the year's IPO success stories, has leased an 83,000-square-foot R&D outpost in its native Cambridge, MA, pressing forward with a pipeline of microbiome treatments.
GlaxoSmithKline is taking a gamble on Idera Pharmaceuticals' antisense drug technology, promising up to $100 million in a collaboration focused on renal disease.